GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year

Yahoo FinanceOct 14 08:39 ET

AstraZeneca's Lung Cancer Drug Enhertu Gets Conditional Approval in China

MT NewswiresOct 14 03:52 ET

Daiichi Sankyo/astrazeneca (AZN.US)'s 'Tecentriq' has been approved in China.

On October 14th, the official website of the China National Medical Products Administration disclosed that the new indication for lung cancer of the injection-type trastuzumab deruxtecan (Enhertu) declared by Daiichi Sankyo has obtained marketing approval. Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate jointly developed by Astrazeneca (AZN.US) and Daiichi Sankyo.

Zhitong FinanceOct 14 02:44 ET

AstraZeneca Expanding R&D Pipeline in China

China DailyOct 13 23:04 ET

GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain

BenzingaOct 11 12:43 ET

Express News | AstraZeneca PLC Reports 9.9% Passive Stake in Conduit Pharmaceuticals Inc as of August 7 - SEC Filing

ReutersOct 11 06:03 ET